A A A
Feed icon

News

John Hardy, PhD, right, accepted the 2015 Robert A. Pritzker Prize from MJFF VP Brian Fiske, PhD, and Michael J. Fox on April 15.

John Hardy awarded 2015 Robert A. Pritzker Prize for Leadership in Parkinson's Research

One of the UK Parkinson's Disease Consortium Principal Investigators, Prof John Hardy, has been awarded the 2015 Robert A. Pritzker Prize for his leadership in Parkinson's genetics research. The award was presented by Michael J. Fox at a ceremony in New York on April 15. From the Michael J. Fox Foundation website: More...

Webcast - Prof Nicholas Wood - Advances in Genetic Understanding of Parkinson's Disease.

Video: Advances in Genetic Understanding of Parkinson's Disease

Webcast of the presentation entitled ‘Advances in Genetic Understanding of Parkinson's Disease’ given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson’s Disease and Beyond, held in December 2014. More...

Pedigrees and I-FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study.

GCH1 gene and Parkinson's risk

A study published in Brain, led by researchers at UCL Institute of Neurology, has shown that genetic mutations which cause a decrease in dopamine production in the brain and lead to a form of childhood-onset Dystonia, also play a role in the development of Parkinson’s disease.
More...

Leonard Wolfson Experimental Neurology Centre (LWENC)

The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials

More...

Audioslide presentation on Claudia Manzoni's paper examining how fibroblasts with LRRK2 mutations react to starvation conditions and the possible deficits that they have in autophagy.

LRRK2 and autophagy in fibroblasts

In this paper Claudia Manzoni studies how fibroblast cells from people with Parkinson’s disease caused by mutations in LRRK2 react to starvation. Although the changes are quite subtle, there are differences between the way that fibroblasts that contain mutant LRRK2 respond to being starved – suggesting that there may be changes in the way that these cells regulate a key process called autophagy (a term which comes from the greek meaning to eat yourself, and is one of the ways that cells get rid of waste and recycle proteins and organellles).
More...

Anthony Schapira

(Principal Investigator)

Tony Schapira


Prof Tony Schapira is the Head of the Department of Clinical Neuroscience at the UCL Institute of Neurology and Chairman of Clinical Neurosciences Specialties.

The primary area of research in the department is the investigation of the aetiology and pathogenesis of neurodegenerative disorders. Specifically the department has an interest in the genetics and biochemistry of Parkinson's disease, Huntington's disease and Friedreich's ataxia. The department has established an international reputation in this area and in the area of diseases of the mitochondrial respiratory chain and inborn errors of mitochondrial function. There are also extensive research programmes on the genetics and pathogenesis of dystonia, motor neurone disease and peripheral nerve disorders. A joint appointment with the Hammersmith Hospital has provided an additional research interest in neuropsychology. Facilities for research are extensive. There are general laboratories for biochemistry, molecular biology, tissue preparation etc, in addition to specialist laboratory space for tissue culture (4 hoods), molecular biology, radioactive work, fluorimetry, spectrophotometry, lipid chemistry and histochemistry. There are advanced facilities for image analysis including an electron microscope.

esearcherID


Contact details

Lab website


Link to Publications RSS button
Jump to: 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1981 | 1980 | 1977
Number of items: 586.

2015

Beavan, M; McNeill, A; Proukakis, C; Hughes, DA; Mehta, A; Schapira, AH; (2015) Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol , 72 (2) 201 - 208. 10.1001/jamaneurol.2014.2950.

Beavan, M; Schapira, AH; (2015) Glucocerebrosidase Gene Mutation and Preclinical Markers of Parkinson Disease-Reply. JAMA Neurol , 72 (6) 724 - . 10.1001/jamaneurol.2015.0484.

Booth, TC; Nathan, M; Waldman, AD; Quigley, AM; Schapira, AH; Buscombe, J; (2015) The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1. AJNR Am J Neuroradiol , 36 (2) 229 - 235. 10.3174/ajnr.A3970.

Booth, TC; Nathan, M; Waldman, AD; Quigley, AM; Schapira, AH; Buscombe, J; (2015) The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2. AJNR Am J Neuroradiol , 36 (2) 236 - 244. 10.3174/ajnr.A3971.

Chaudhuri, KR; Sauerbier, A; Rojo, JM; Sethi, K; Schapira, AH; Brown, RG; Antonini, A; (2015) The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord , 21 (3) 287 - 291. 10.1016/j.parkreldis.2014.12.031.

Hockey, LN; Kilpatrick, BS; Eden, E; Lin-Moshier, Y; Brailoiu, GC; Brailoiu, E; Futter, CE; (2015) Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by two-pore channel 2 inhibition. Journal of Cell Science , 128 pp. 232-238. 10.1242/​jcs.164152. Green open access
file

Kiely, AP; Ling, H; Asi, YT; Kara, E; Limousin, P; Lewis, P; Proukakis, C; (2015) Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. In: NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. (pp. 31 - 31).

Löhle, M; Hughes, D; Milligan, A; Richfield, L; Reichmann, H; Mehta, A; Schapira, AH; (2015) Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology , 84 (14) 1454 - 1464. 10.1212/WNL.0000000000001450.

Mullin, S; Schapira, AH; (2015) Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurol Clin , 33 (1) 1 - 17. 10.1016/j.ncl.2014.09.010.

Nalls, MA; Bras, J; Hernandez, DG; Keller, MF; Majounie, E; Renton, AE; Saad, M; (2015) NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging , 36 (3) 1605.e7 - 1605.12. 10.1016/j.neurobiolaging.2014.07.028.

Porcari, R; Proukakis, C; Waudby, CA; Bolognesi, B; Mangione, PP; Paton, JF; Mullin, S; (2015) The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein. J Biol Chem , 290 (4) 2395 - 2404. 10.1074/jbc.M114.610527. Green open access
file

Schapira, AH; (2015) Glucocerebrosidase and Parkinson disease: Recent advances. Mol Cell Neurosci 10.1016/j.mcn.2015.03.013.

Schapira, AH; (2015) The measurement and importance of non-motor symptoms in Parkinson disease. Eur J Neurol , 22 (1) 2 - 3. 10.1111/ene.12523.

Schapira, AH; Albanese, A; Brainin, M; Davie, C; Juvela, S; Leone, M; Meschia, J; (2015) Sirkka-Liisa Leinonen. Eur J Neurol 10.1111/ene.12697.

Tofaris, GK; Schapira, AH; (2015) Neurodegenerative diseases in the era of targeted therapeutics: how to handle a tangled issue. Mol Cell Neurosci 10.1016/j.mcn.2015.03.002.

2014

Beilina, A; Rudenko, IN; Kaganovich, A; Civiero, L; Chau, H; Kalia, SK; Kalia, LV; (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A , 111 (7) 2626 - 2631. 10.1073/pnas.1318306111.

Cooper, JM; Wiklander, PB; Nordin, JZ; Al-Shawi, R; Wood, MJ; Vithlani, M; Schapira, AH; (2014) Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord , 29 (12) 1476 - 1485. 10.1002/mds.25978. Green open access
file

Dong, J; Gao, J; Nalls, M; Gao, X; Huang, X; Han, J; Singleton, AB; (2014) Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiol Aging , 35 (6) 1512.e5 - 1512.10. 10.1016/j.neurobiolaging.2013.12.020.

Gkotsi, D; Begum, R; Salt, T; Lascaratos, G; Hogg, C; Chau, KY; Schapira, AH; (2014) Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Exp Eye Res , 122 pp. 50-53. 10.1016/j.exer.2014.02.023. Green open access
file

Gómez-Sánchez, R; Gegg, ME; Bravo-San Pedro, JM; Niso-Santano, M; Alvarez-Erviti, L; Pizarro-Estrella, E; Gutiérrez-Martín, Y; (2014) Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiol Dis , 62 426-440. 10.1016/j.nbd.2013.10.021. Green open access
file

Hauser, RA; Gordon, MF; Mizuno, Y; Poewe, W; Barone, P; Schapira, AH; Rascol, O; (2014) Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis , 2014 467131 - ?. 10.1155/2014/467131.

Hauser, RA; Schapira, AH; Barone, P; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2014) Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol , 21 (5) 736 - 743.

Kiely, AP; Asi, YT; Kara, E; Limousin, P; Ling, H; Lewis, P; Proukakis, C; (2014) How do G51D SNCA mutation cases compare clinically and neuropathologically to SNCA duplication and H50Q SNCA mutation? In: NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. (pp. 11 - 12).

Löhle, M; Ramberg, CJ; Reichmann, H; Schapira, AH; (2014) Early versus delayed initiation of pharmacotherapy in Parkinson's disease. Drugs , 74 (6) 645 - 657. 10.1007/s40265-014-0209-5.

Marin, C; Bonastre, M; Mengod, G; Cortés, R; Giralt, A; Obeso, JA; Schapira, AH; (2014) Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. Neurobiol Dis , 64 36 - 47. 10.1016/j.nbd.2013.12.009.

McNeill, A; Magalhaes, J; Shen, C; Chau, KY; Hughes, D; Mehta, A; Foltynie, T; (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain , 137 (5) pp. 1481-1495. 10.1093/brain/awu020. Green open access
file

McNeill, A; Roberti, G; Lascaratos, G; Hughes, D; Mehta, A; Garway-Heath, DF; Schapira, AHV; (2014) Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study (vol 109, pg 221, 2013). MOLECULAR GENETICS AND METABOLISM , 111 (3) 408 - 408. 10.1016/j.ymgme.2013.12.297.

Nalls, MA; Pankratz, N; Lill, CM; Do, CB; Hernandez, DG; Saad, M; DeStefano, AL; (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet , 46 (9) 989 - 993. 10.1038/ng.3043.

Nalls, MA; Saad, M; Noyce, AJ; Keller, MF; Schrag, A; Bestwick, JP; Traynor, BJ; (2014) Genetic comorbidities in Parkinson's disease. Hum Mol Genet , 23 (3) 831 - 841. 10.1093/hmg/ddt465.

Proukakis, C; Shoaee, M; Morris, J; Brier, T; Kara, E; Sheerin, UM; Charlesworth, G; (2014) Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations. Mov Disord , 29 (8) 060-1064. 10.1002/mds.25883. Green open access
file

Schapira, AH; (2014) Recent advances in neurology 2013-2014. Eur J Neurol , 21 (12) 1425 - 1434. 10.1111/ene.12619.

Schapira, AH; Olanow, CW; Greenamyre, JT; Bezard, E; (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet , 384 (9942) 545 - 555. 10.1016/S0140-6736(14)61010-2.

Schapira, AH; Patel, S; (2014) Targeting mitochondria for neuroprotection in Parkinson disease. JAMA Neurol , 71 (5) 537 - 538. 10.1001/jamaneurol.2014.64.

Zokaei, N; McNeill, A; Proukakis, C; Beavan, M; Jarman, P; Korlipara, P; Hughes, D; (2014) Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain , 137 (Pt 8) 2303 - 2311. 10.1093/brain/awu143.

2013

Alvarez-Erviti, L; Seow, Y; Schapira, AH; Rodriguez-Oroz, MC; Obeso, JA; Cooper, JM; (2013) Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease. Cell Death Dis , 4 e545 - ?. 10.1038/cddis.2013.73. Gold open access

Batla, A; Stamelou, M; Mencacci, N; Schapira, AH; Bhatia, KP; (2013) Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease. Mov Disord , 28 (8) 1159 - 1160. 10.1002/mds.25318. Green open access
file

Beavan, MS; Schapira, AH; (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med , 45 (8) 511 - 521. 10.3109/07853890.2013.849003.

Berg, D; Lang, AE; Postuma, RB; Maetzler, W; Deuschl, G; Gasser, T; Siderowf, A; (2013) Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol , 12 (5) 514 - 524. 10.1016/S1474-4422(13)70047-4.

Chau, KY; Cooper, JM; Schapira, AH; (2013) Pramipexole reduces phosphorylation of α-Synuclein at Serine-129. Journal of Molecular Neuroscience , 51 pp. 573-580. 10.1007/s12031-013-0030-8. Green open access
filefilefilefilefilefile

Cleeter, MW; Chau, KY; Gluck, C; Mehta, A; Hughes, DA; Duchen, M; Wood, NW; (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int , 62 (1) 1 - 7. 10.1016/j.neuint.2012.10.010. Gold open access

Duran, R; Mencacci, NE; Angeli, AV; Shoai, M; Deas, E; Houlden, H; Mehta, A; (2013) The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders , 28 (2) 232 - 236. 10.1002/mds.25248. Green open access
file

Ferreira, JJ; Katzenschlager, R; Bloem, BR; Bonuccelli, U; Burn, D; Deuschl, G; Dietrichs, E; (2013) Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol , 20 (1) 5 - 15. 10.1111/j.1468-1331.2012.03866.x.

Holmans, P; Moskvina, V; Jones, L; Sharma, M; International Parkinson's Disease Genomics Consortium, ; Vedernikov, A; Buchel, F; (2013) A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet , 22 (5) 1039 - 1049. 10.1093/hmg/dds492.

Kilpatrick, BS; Eden, ER; Schapira, AH; Futter, CE; Patel, S; (2013) Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. J Cell Sci , 126 (Pt 1) 60 - 66. 10.1242/jcs.118836.

Klebe, S; Golmard, JL; Nalls, MA; Saad, M; Singleton, AB; Bras, JM; Hardy, J; (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. Journal of Neurology, Neurosurgery and Psychiatry , 84 (6) 666 - 673. 10.1136/jnnp-2012-304475. Green open access
file

Manzoni, C; Mamais, A; Dihanich, S; McGoldrick, P; Devine, MJ; Zerle, J; Kara, E; (2013) Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun , 441 (4) 862 - 866. 10.1016/j.bbrc.2013.10.159.

McNeill, A; Healy, DG; Schapira, AH; Taanman, JW; (2013) Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations. Mol Genet Metab , 109 (4) 402 - 403. 10.1016/j.ymgme.2013.06.002.

McNeill, A; Roberti, G; Lascaratos, G; Hughes, D; Mehta, A; Garway-Heath, DF; Schapira, AH; (2013) Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. Molecular Genetics and Metabolism , 109 (2) 221 - 223. 10.1016/j.ymgme.2013.04.001. Green open access
file

McNeill, A; Wu, RM; Tzen, KY; Aguiar, PC; Arbelo, JM; Barone, P; Bhatia, K; (2013) Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLOS ONE , 8 (7) , Article e69190. 10.1371/journal.pone.0069190. Green open access
file

Mullin, S; Schapira, A; (2013) α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol , 47 (2) 587 - 597. 10.1007/s12035-013-8394-x.

Olanow, CW; Schapira, AH; (2013) Therapeutic prospects for Parkinson disease. Ann Neurol , 74 (3) 337 - 347. 10.1002/ana.24011.

Osellame, LD; Rahim, AA; Hargreaves, IP; Gegg, ME; Richard-Londt, A; Brandner, S; Waddington, SN; (2013) Mitochondria and quality control defects in a mouse model of Gaucher Disease-links to Parkinson's Disease. Cell Metabolism , 17 (6) pp. 941-953. 10.1016/j.cmet.2013.04.014. Green open access
filefile

Pichler, I; Del Greco, MF; Gogele, M; Lill, CM; Bertram, L; Do, CB; Eriksson, N; (2013) Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS.Med. , 10 (6) , Article e1001462. 10.1371/journal.pmed.1001462. Green open access
file

Proukakis, C; Dudzik, CG; Brier, T; MacKay, DS; Cooper, JM; Millhauser, GL; Houlden, H; (2013) A novel α-synuclein missense mutation in Parkinson disease. Neurology , 80 (11) 1062 - 1064. 10.1212/WNL.0b013e31828727ba.

Proukakis, C; Houlden, H; Schapira, AH; (2013) Somatic alpha-synuclein mutations in Parkinson's disease: Hypothesis and preliminary data. Movement Disorders 10.1002/mds.25502. Green open access
file

Ray Chaudhuri, K; Rojo, JM; Schapira, AH; Brooks, DJ; Stocchi, F; Odin, P; Antonini, A; (2013) A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One , 8 (2) , Article e57221. 10.1371/journal.pone.0057221. Green open access
file

Sarkozy, A; Hicks, D; Hudson, J; Laval, SH; Barresi, R; Hilton-Jones, D; Deschauer, M; (2013) ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation. Hum Mutat , 34 (8) 1111 - 1118. 10.1002/humu.22342.

Schapira, AH; (2013) Progress in European neurology 2012-2013. Eur J Neurol , 20 (12) 1499 - 1507. 10.1111/ene.12303.

Schapira, AH; (2013) Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol , 26 (4) 395 - 400. 10.1097/WCO.0b013e3283633741. Green open access
file

Schapira, AH; (2013) Calcium dysregulation in Parkinson's disease. Brain , 136 (Pt 7) 2015 - 2016. 10.1093/brain/awt180.

Schapira, AH; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2013) Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol , 20 (1) 180 - 187. 10.1111/j.1468-1331.2012.03822.x.

Schapira, AH; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2013) Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol , 20 (1) 50 - 56. 10.1111/j.1468-1331.2012.03712.x.

Schapira, AH; Gegg, ME; (2013) Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci U S A , 110 (9) 3214 - 3215. 10.1073/pnas.1300822110.

Schapira, AH; McDermott, MP; Barone, P; Comella, CL; Albrecht, S; Hsu, HH; Massey, DH; (2013) Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol , 12 (8) 747 - 755. 10.1016/S1474-4422(13)70117-0.

Schapira, AH; Stocchi, F; Borgohain, R; Onofrj, M; Bhatt, M; Lorenzana, P; Lucini, V; (2013) Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol , 20 (2) 271 - 280. 10.1111/j.1468-1331.2012.03840.x.

Schapira, AHV; (2013) Mitochondrial diseases. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , 43 1 - 1.

Warren Olanow, C; Kieburtz, K; Rascol, O; Poewe, W; Schapira, AH; Emre, M; Nissinen, H; (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord , 28 (8) 1064 - 1071. 10.1002/mds.25364.

deSouza, RM; Moro, E; Lang, AE; Schapira, AH; (2013) Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol , 73 (5) 565 - 575. 10.1002/ana.23890. Green open access
file

2012

Cnop, M; Igoillo-Esteve, M; Rai, M; Begu, A; Serroukh, Y; Depondt, C; Musuaya, AE; (2012) Central role and mechanisms of β-cell dysfunction and death in friedreich ataxia-associated diabetes. Ann Neurol , 72 (6) 971 - 982. 10.1002/ana.23698.

Devine, MJ; Kaganovich, A; Ryten, M; Mamais, A; Trabzuni, D; Manzoni, C; McGoldrick, P; (2012) Correction: Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLOS ONE , 7 (1) , Article e22489. 10.1371/annotation/c12e4f9e-5aae-424b-a69f-fddf16976dc5. Green open access
file

Duran, R; McNeill, A; Mehta, A; Hughes, D; Cox, T; Deegan, P; Schapira, AH; (2012) Novel pathogenic mutations in the glucocerebrosidase locus. Mol Genet Metab , 106 (4) 495 - 497. 10.1016/j.ymgme.2012.05.006. Gold open access

Gardiner, AR; Bhatia, KP; Stamelou, M; Dale, RC; Kurian, MA; Schneider, SA; Wali, GM; (2012) PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology , 79 (21) 2115 - 2121. 10.1212/WNL.0b013e3182752c5a.

Gegg, ME; Burke, D; Heales, SJ; Cooper, JM; Hardy, J; Wood, NW; Schapira, AH; (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol , 72 (3) 455 - 463. 10.1002/ana.23614.

Keller, MF; Saad, M; Bras, J; Bettella, F; Nicolaou, N; Simón-Sánchez, J; Mittag, F; (2012) Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet , 21 (22) 4996 - 5009. 10.1093/hmg/dds335.

Klionsky, DJ; Abdalla, FC; Abeliovich, H; Abraham, RT; Acevedo-Arozena, A; Adeli, K; Agholme, L; (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy , 8 (4) 445 - 544.

Lascaratos, G; Garway-Heath, DF; Willoughby, CE; Chau, KY; Schapira, AH; (2012) Mitochondrial dysfunction in glaucoma: understanding genetic influences. Mitochondrion , 12 (2) 202 - 212. 10.1016/j.mito.2011.11.004.

McNeill, A; Duran, R; Hughes, DA; Mehta, A; Schapira, AH; (2012) A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. [Letter]. Journal of Neurology, Neurosurgery & Psychiatry , 83 (8) 853 -854. 10.1136/jnnp-2012-302402. Green open access
file

McNeill, A; Duran, R; Proukakis, C; Bras, J; Hughes, D; Mehta, A; Hardy, J; (2012) Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord , 27 (4) 526 - 532. 10.1002/mds.24945.

Mittag, F; Büchel, F; Saad, M; Jahn, A; Schulte, C; Bochdanovits, Z; Simón-Sánchez, J; (2012) Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. Hum Mutat , 33 (12) 1708 - 1718. 10.1002/humu.22161.

Mizuno, Y; Yamamoto, M; Kuno, S; Hasegawa, K; Hattori, N; Kagimura, T; Sarashina, A; (2012) Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol , 35 (4) 174 - 181. 10.1097/WNF.0b013e31825f77b9.

Osellame, LD; Rahim, A; Gegg, ME; Waddington, S; Schapira, AHV; Duchen, MR; (2012) Accumulation of damaged mitochondria in neuropathic Gaucher disease, the most prevalent risk factor for Parkinson's disease, is due to defective cellular degradation machinery. In: BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS. (pp. S79 - S80).

Papkovskaia, TD; Chau, KY; Inesta-Vaquera, F; Papkovsky, DB; Healy, DG; Nishio, K; Staddon, J; (2012) G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet , 21 (19) 4201 - 4213. 10.1093/hmg/dds244. Gold open access

Schapira, AH; (2012) Mitochondrial diseases. Lancet , 379 (9828) 1825 - 1834. 10.1016/S0140-6736(11)61305-6.

Schapira, AH; (2012) Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal , 16 (9) 965 - 973. 10.1089/ars.2011.4419.

Schapira, AH; Hillbom, M; (2012) Advances in neurology 2011-12. Eur J Neurol , 19 (10) 1267 - 1275. 10.1111/j.1468-1331.2012.03870.x.

Schapira, AH; Tan, EK; (2012) Optimizing treatment for Parkinson's disease. Eur J Neurol , 19 (12) 1483 - 1486. 10.1111/ene.12025.

Stocchi, F; Borgohain, R; Onofrj, M; Schapira, AH; Bhatt, M; Lucini, V; Giuliani, R; (2012) A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord , 27 (1) 106 - 112. 10.1002/mds.23954.

Wray, S; Self, M; NINDS Parkinson's Disease iPSC Consortium, ; NINDS Huntington's Disease iPSC Consortium, ; NINDS ALS iPSC Consortium, ; Lewis, PA; Taanman, JW; (2012) Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLOS One , 7 (8) , Article e43099. 10.1371/journal.pone.0043099. Green open access
file

2011

Abramov, AY; Gegg, M; Grunewald, A; Wood, NW; Klein, C; Schapira, AHV; (2011) Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease. PLOS ONE , 6 (10) , Article e25622. 10.1371/journal.pone.0025622. Green open access
file

Alvarez-Erviti, L; Seow, Y; Schapira, AH; Gardiner, C; Sargent, IL; Wood, MJA; Cooper, JM; (2011) Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. NEUROBIOL DIS , 42 (3) 360 - 367. 10.1016/j.nbd.2011.01.029. Gold open access

Brainin, M; Berardelli, A; Boon, P; Gilhus, NE; Leys, D; Ludolph, A; Schapira, AHV; (2011) Comment from the EFNS Scientific Committee on the letter from Gunther Haag concerning Bendsten L et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17: 1318-1325. EUR J NEUROL , 18 (7) E83 - E84. 10.1111/j.1468-1331.2011.03382.x.

Devine, MJ; Kaganovich, A; Ryten, M; Mamais, A; Trabzuni, D; Manzoni, C; McGoldrick, P; (2011) Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLOS ONE , 6 (7) , Article e22489. 10.1371/journal.pone.0022489. Green open access
file

Devine, MJ; Ryten, M; Vodicka, P; Thomson, AJ; Burdon, T; Houlden, H; Cavaleri, F; (2011) Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. NAT COMMUN , 2 , Article 440. 10.1038/ncomms1453. Gold open access

Gegg, ME; Schapira, AHV; (2011) PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2 Implications for Parkinson disease pathogenesis. AUTOPHAGY , 7 (2) 243 - 245. 10.4161/auto.7.2.14332.

Meissner, WG; Frasier, M; Gasser, T; Goetz, CG; Lozano, A; Piccini, P; Obeso, JA; (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov , 10 (5) 377 - 393. 10.1038/nrd3430.

Plagnol, V; Nalls, MA; Bras, JM; Hernandez, DG; Sharma, M; Sheerin, UM; Saad, M; (2011) A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease. PLoS Genetics , 7 (6) , Article e1002142. 10.1371/journal.pgen.1002142. Green open access
file

Poewe, W; Rascol, O; Barone, P; Hauser, RA; Mizuno, Y; Haaksma, M; Salin, L; (2011) Extended-release pramipexole in early Parkinson disease A 33-week randomized controlled trial. NEUROLOGY , 77 (8) 759 - 766.

Schapira, AH; (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs , 25 (12) 1061 - 1071. 10.2165/11596310-000000000-00000.

Schapira, AH; (2011) Mitochondrial pathology in Parkinson's disease. Mt Sinai J Med , 78 (6) 872 - 881. 10.1002/msj.20303.

Schapira, AH; (2011) Aetiopathogenesis of Parkinson's disease. J Neurol , 258 (Suppl 2) S307 - S310. 10.1007/s00415-011-6016-y.

Schapira, AH; Gegg, M; (2011) Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinson's Disease , 2011 , Article 159160. 10.4061/2011/159160. Green open access
file

Schapira, AH; Hillbom, M; (2011) Publishing changes and information delivery in the clinical neurosciences. Eur J Neurol , 18 (12) 1365 - 1372. 10.1111/j.1468-1331.2011.03594.x.

Schapira, AH; Jenner, P; (2011) Etiology and Pathogenesis of Parkinson's Disease. MOVEMENT DISORD , 26 (6) 1049 - 1055. 10.1002/mds.23732.

Schapira, AHV; (2011) Challenges to the development of disease-modifying therapies in Parkinson's disease. EUR J NEUROL , 18 16 - 21. 10.1111/j.1468-1331.2010.03324.x.

Schapira, AHV; (2011) The management of Parkinson's disease - what is new? EUR J NEUROL , 18 1 - 2. 10.1111/j.1468-1331.2010.03323.x.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Salin, L; (2011) Extended-release pramipexole in advanced Parkinson disease A randomized controlled trial. NEUROLOGY , 77 (8) 767 - 774.

Schapira, AHV; Schrag, A; (2011) Parkinson disease clinical subtypes and their implications. NAT REV NEUROL , 7 (5) 247 - 248. 10.1038/nrneurol.2011.40.

Sivam, D; Rizos, A; Martin, A; Naidu, Y; Renton, T; Schapira, AHV; Martinez-Martin, P; (2011) Pain in Parkinson's disease: Observational study of 225 patients. In: MOVEMENT DISORDERS. (pp. S182 - S182).

Stocchi, F; Giorgi, L; Hunter, B; Schapira, AHV; (2011) PREPARED: Comparison of Prolonged and Immediate Release Ropinirole in Advanced Parkinson's Disease. MOVEMENT DISORD , 26 (7) 1259 - 1265. 10.1002/mds.23498.

Tan, EK; Schapira, AH; (2011) LRRK2 as a therapeutic target in Parkinson's disease. EUR J NEUROL , 18 (4) 545 - 546. 10.1111/j.1468-1331.2010.03305.x.

Tan, EK; Schapira, AH; (2011) New LRRK2 variants identified in Parkinson's disease. EUR J NEUROL , 18 (3) 369 - 370. 10.1111/j.1468-1331.2010.03163.x.

2010

Schapira, AH and Fahn, S and Lang, AET (Eds). (2010) Movement Disorders 4: Blue Book Neurology Series. (Vol.34). Elsevier Health Sciences

Alvarez-Erviti, L; Rodriguez-Oroz, MC; Cooper, JM; Caballero, C; Ferrer, I; Obeso, JA; Schapira, AHV; (2010) Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. ARCH NEUROL-CHICAGO , 67 (12) 1464 - 1472. 10.1001/archneuro1.2010.198.

Chau, KY; Cooper, JM; Schapira, AHV; (2010) Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. NEUROCHEM INT , 57 (5) 525 - 529. 10.1016/j.neuint.2010.06.017.

Chaudhuri, KR; Prieto-Jurcynska, C; Naidu, Y; Mitra, T; Frades-Payo, B; Tluk, S; Ruessmann, A; (2010) The Nondeclaration of Nonmotor Symptoms of Parkinson's Disease to Health Care Professionals: An International Study Using the Nonmotor Symptoms Questionnaire. MOVEMENT DISORD , 25 (6) 704 - 709. 10.1002/mds.22868.

Gegg, ME; Cooper, JM; Chau, KY; Rojo, M; Schapira, AHV; Taanman, JW; (2010) Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. HUM MOL GENET , 19 (24) 4861 - 4870. 10.1093/hmg/ddq419.

Grunewald, A; Voges, L; Rakovic, A; Kasten, M; Kock, N; Schapira, AHV; Orolicki, S; (2010) Impact of Mutations in Parkin on Mitochondrial Function and Morphology. In: NEUROLOGY. (pp. A261 - A261). LIPPINCOTT WILLIAMS & WILKINS

Grunewald, A; Voges, L; Rakovic, A; Kasten, M; Vandebona, H; Hemmelmann, C; Lohmann, K; (2010) Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLOS ONE , 5 (9) , Article e12962. 10.1371/journal.pone.0012962. Green open access
file

Hauser, RA; Schapira, AHV; Rascol, O; Barone, P; Mizuno, Y; Salin, L; Haaksma, M; (2010) Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease. MOVEMENT DISORD , 25 (15) 2542 - 2549. 10.1002/mds.23317.

Kajihara, M; Montagnese, S; Khanna, P; Amodio, P; Schapira, AH; Dusheiko, GM; Morgan, MY; (2010) Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases. Eur.J.Gastroenterol.Hepatol. , 22 (5) 628 - 631.

Kajihara, M; Montagnese, S; Khanna, P; Amodio, P; Schapira, AHV; Dusheiko, GM; Morgan, MY; (2010) Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha 2b: a report of two cases. EUR J GASTROEN HEPAT , 22 (5) 628 - 631. 10.1097/MEG.0b013e32833383e3.

Obeso, JA; Rodriguez-Oroz, MC; Goetz, CG; Marin, C; Kordower, JH; Rodriguez, M; Hirsch, EC; (2010) Missing pieces in the Parkinson's disease puzzle. NAT MED , 16 (6) 653 - 661.

Rajagopalan, B; Francis, JM; Cooke, F; Korlipara, LVP; Blamire, AM; Schapira, AHV; Madan, J; (2010) Analysis of the Factors Influencing the Cardiac Phenotype in Friedreich's Ataxia. MOVEMENT DISORD , 25 (7) 846 - 852. 10.1002/mds.22864.

Rascol, O; Barone, P; Hauser, RA; Mizuno, Y; Poewe, W; Schapira, AHV; Salin, L; (2010) Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease. MOVEMENT DISORD , 25 (14) 2326 - 2332. 10.1002/mds.23262.

Schapira, A; (2010) Parkinson's Disease in Daily Practice. John Wiley & Sons Inc

Schapira, AHV; (2010) Safinamide in the treatment of Parkinson's disease. EXPERT OPIN PHARMACO , 11 (13) 2261 - 2268. 10.1517/14656566.2010.511612.

Schapira, AHV; (2010) Complex I: Inhibitors, inhibition and neurodegeneration. EXP NEUROL , 224 (2) 331 - 335. 10.1016/j.expneurol.2010.03.028.

Schapira, AHV; (2010) Movement disorders: advances in cause and treatment. LANCET NEUROL , 9 (1) 6 - 7.

Schapira, AHV; (2010) Future Strategies for Neuroprotection in Parkinson's Disease. NEURODEGENER DIS , 7 (1-3) 210 - 212. 10.1159/000295666.

Schapira, AHV; Albrecht, S; Barone, P; Comella, CL; McDermott, MP; Mizuno, Y; Poewe, W; (2010) Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study. MOVEMENT DISORD , 25 (11) 1627 - 1632. 10.1002/mds.23143.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2010) Comparisons among responses to pramipexole extended-release as adjunctive treatment in Japanese and non-Japanese studies of advanced Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 374 - 374). WILEY-BLACKWELL

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2010) Sustained off-time decrease in patients using pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 100 - 100). WILEY-BLACKWELL

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Salin, L; (2010) Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S309 - S309). WILEY-LISS

Schapira, AHV; Fox, S; Hauser, R; Jankovic, J; Kulisevsky, J; Pahwa, R; Poewe, W; (2010) SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S308 - S309). WILEY-LISS

Schapira, AHV; Tolosa, E; (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. NAT REV NEUROL , 6 (6) 309 - 317. 10.1038/nrneurol.2010.52.

Tan, EK; Schapira, AH; (2010) Summary of GIGYF2 studies in Parkinson's disease: the burden of proof. EUR J NEUROL , 17 (2) 175 - 176. 10.1111/j.1468-1331.2009.02834.x.

Turner, C; Schapira, AHV; (2010) Mitochondrial matters of the brain: the role in Huntington's disease. J BIOENERG BIOMEMBR , 42 (3) 193 - 198. 10.1007/s10863-010-9290-y.

2009

Bhattacharyya, S; Schapira, AH; Mikhailidis, DP; Davar, J; (2009) Drug-induced fibrotic valvular heart disease. LANCET , 374 (9689) 577 - 585.

Cano, SJ; Riazi, A; Schapira, AHV; Cooper, JM; Hobart, JC; (2009) Friedreich's Ataxia Impact Scale: A New Measure Striving to Provide the Flexibility Required by Today's Studies. MOVEMENT DISORD , 24 (7) 984 - 992. 10.1002/mds.22420.

Chau, KY; Ching, HL; Schapira, AHV; Cooper, JM; (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J NEUROCHEM , 110 (3) 1005 - 1013. 10.1111/j.1471-4159.2009.06191.x.

Chau, KY; Korlipara, LVP; Cooper, JM; Schapira, AHV; (2009) Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J NEUROL SCI , 278 (1-2) 44 - 53. 10.1016/j.jns.2008.11.012.

Chaudhuri, KR; Martinez-Martin, P; Sherman, R; Naidu, Y; Odin, P; Sethi, K; Ondo, W; (2009) The Non Motor Staging of Parkinson's Disease: Results from an International Study. In: NEUROLOGY. (pp. A322 - A322). LIPPINCOTT WILLIAMS & WILKINS

Chaudhuri, KR; Schapira, AHV; (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. LANCET NEUROL , 8 (5) 464 - 474.

Gallagher, DA; Schapira, AHV; (2009) Etiopathogenesis and Treatment of Parkinson's Disease. CURR TOP MED CHEM , 9 (10) 860 - 868.

Gegg, ME; Cooper, JM; Schapira, AHV; Taanman, JW; (2009) Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells. PLOS ONE , 4 (3) , Article e4756. 10.1371/journal.pone.0004756. Green open access
file

Grunewald, A; Gegg, ME; Taanman, JW; King, RH; Kock, N; Klein, C; Schapira, AHV; (2009) Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. EXP NEUROL , 219 (1) 266 - 273. 10.1016/j.expneurol.2009.05.027.

Martinez-Martin, P; Sherman, R; Naidu, Y; Richards, C; Odin, P; Stocchi, F; Macphee, G; (2009) Non- motor staging of Parkinson's disease (PD) and early longitudinal follow up results from an international study. In: MOVEMENT DISORDERS. (pp. S385 - S385). WILEY-LISS

Naidu, Y; Martinez-Martin, P; Mitra, T; Tluk, S; Stocchi, F; Macphee, G; Odin, P; (2009) Non declaration of non motor symptoms (NMS) of PD: An international study using the NMSQuest. In: MOVEMENT DISORDERS. (pp. S386 - S386). WILEY-LISS

Nissinen, H; Kuoppamaki, M; Leinonen, M; Schapira, AH; (2009) Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. EUR J NEUROL , 16 (12) 1305 - 1311. 10.1111/j.1468-1331.2009.02726.x.

Obeso, JA; Schapira, AH; (2009) Compensatory Mechanisms in Parkinson's Disease. MOVEMENT DISORD , 24 (1) 153 - 154. 10.1002/mds.22177.

Reddy, P; Naidu, Y; Suleyman, N; Tluk, S; Odin, P; Macphee, G; Stocchi, F; (2009) Characterisation of Restless Legs like syndrome in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S375 - S375). WILEY-LISS

Schapira, A; Hartmann, A; Agid, Y; (2009) Parkinsonian Disorders in Clinical Practice. Wiley-Blackwell

Schapira, A; Hartmann, A; Agid, Y; (2009) Parkinsonian Disorders in Clinical Practice. Whiley Blackwell

Schapira, AH; Agid, Y; Barone, P; Jenner, P; Lemke, MR; Poewe, W; Rascol, O; (2009) Perspectives on recent advances in the understanding and treatment of Parkinson's disease. EUR J NEUROL , 16 (10) 1090 - 1099. 10.1111/j.1468-1331.2009.02793.x.

Schapira, AH; Olanow, CW; (2009) Initiating Therapy in Parkinson's Disease Reply. ANN NEUROL , 65 (4) 481 - 481. 10.1002/ana.21690.

Schapira, AHV; (2009) Disease modifying agents in Parkinson's disease? In: JOURNAL OF THE NEUROLOGICAL SCIENCES. (pp. S46 - S46). ELSEVIER SCIENCE BV

Schapira, AHV; (2009) Etiology and Pathogenesis of Parkinson Disease. NEUROL CLIN , 27 (3) 583 - +. 10.1016/j.ncl.2009.04.004.

Schapira, AHV; (2009) Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. NEUROLOGY , 72 S44 - S50.

Schapira, AHV; (2009) Neurobiology and treatment of Parkinson's disease. TRENDS PHARMACOL SCI , 30 (1) 41 - 47. 10.1016/j.tips.2008.10.005.

Schapira, AHV; Emre, M; Jenner, P; Poewe, W; (2009) Levodopa in the treatment of Parkinson's disease. EUR J NEUROL , 16 (9) 982 - 989. 10.1111/j.1468-1331.2009.02697.x.

Taanman, JW; Daras, M; Albrecht, J; Davie, CA; Mallam, EA; Muddle, JR; Weatherall, M; (2009) Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). NEUROMUSCULAR DISORD , 19 (2) 151 - 154. 10.1016/j.nmd.2008.11.002.

Taanman, JW; Rahman, S; Pagnamenta, AT; Morris, AAM; Bitner-Glindzicz, M; Wolf, NI; Leonard, JV; (2009) Analysis of Mutant DNA Polymerase gamma in Patients With Mitochondrial DNA Depletion. HUM MUTAT , 30 (2) 248 - 254. 10.1002/humu.20852.

Tolosa, E; Chaudhuri, KR; Schapira, A; Poewe, W; (2009) Non-Motor Symptoms of Parkinson's Disease. Oxford Univ Pr

Warner, TT; (2009) The genetics and pathogenesis of dystonia. In: Schapira, AHV and Lang, AE and Fahn, S, (eds.) Movement Disorders 4. (457 - 473). Elsevier: Philadelphia.

Webb, T; Mead, S; Beck, J; Uphill, J; Pal, S; Hampson, S; Wadsworth, JDF; (2009) Seven-year discordance in age at onset in monozygotic twins with inherited prion disease (P102L). NEUROPATH APPL NEURO , 35 (4) 427 - 432. 10.1111/j.1365-2990.2009.01012.x.

2008

Barone, P; Schapira, AHV; Debieuvre, CD; Massey, D; (2008) Design of a randomized, placebo-controlled trial of pramipexole in patients with Parkinson's disease and depressive symptoms. In: MOVEMENT DISORDERS. (pp. S199 - S199). WILEY-LISS

Bet, L; Bareggi, SR; Pacei, F; Bondiolotti, G; Meola, G; Schapira, AHV; (2008) Bimodal administration of entacapone in Parkinson's disease patients improves motor control. EUR J NEUROL , 15 (3) 268 - 273. 10.1111/j.1468-1331.2007.02043.x.

Cooper, JM; Korlipara, LVP; Hart, PE; Bradley, JL; Schapira, AHV; (2008) Coenzyme Q(10) and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q(10) therapy. EUR J NEUROL , 15 (12) 1371 - 1379. 10.1111/j.1468-1331.2008.02318.x.

DiFrancesco, JC; Cooper, JM; Lam, A; Hart, PE; Tremolizzo, L; Ferrarese, C; Schapira, AH; (2008) MELAS mitochondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines. EXP NEUROL , 212 (1) 152 - 156. 10.1016/j.expneurol.2008.03.015.

Grosset, DG; Schapira, AH; (2008) Timing the initiation of treatment in Parkinson's disease. J NEUROL NEUROSUR PS , 79 (6) 615 - 615. 10.1136/jnnp.2008.144741.

Healy, DG; Falchi, M; O'Sullivan, SS; Bonifati, V; Durr, A; Bressman, S; Brice, A; (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. LANCET NEUROL , 7 (7) 583 - 590. 10.1016/S1474-4422(08)70117-0. Gold open access

Healy, DG; Wood, NW; Schapira, AH; (2008) Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol , 8 (6) 381 - 385. 10.1136/jnnp.2008.162420.

Martinez, C; Finnern, HW; Rietbrock, S; Eaton, S; Chaudhuri, KR; Schapira, AHV; (2008) Patterns of treatment for restless legs syndrome in primary care in the united kingdom. CLIN THER , 30 (2) 405 - 418. 10.1016/j.clinthera.2008.02.001.

Olanow, CW; Kleburtz, K; Schapira, AHV; (2008) Why Have We Failed to Achieve Neuroprotection in Parkinson's Disease? ANN NEUROL , 64 (6) S101 - S110. 10.1002/ana.21461.

Rohrer, JD; Schapira, AH; (2008) Transient Horner's syndrome during lumbar epidural anaesthesia. EUR J NEUROL , 15 (5) 530 - 531. 10.1111/j.1468-1331.2008.02120.x.

Schapira, AH; (2008) Progress in Parkinson's disease. EUR J NEUROL , 15 (1) 1 - 1. 10.1111/j.1468-1331.2007.02036.x.

Schapira, AH; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: The impact of early vs. delayed treatment with prampiexole on new onset Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S194 - S194). WILEY-LISS

Schapira, AH; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S194 - S194). WILEY-LISS

Schapira, AHV; (2008) Mitochondrial Dysfunction in Neurodegenerative Diseases. NEUROCHEM RES , 33 (12) 2502 - 2509. 10.1007/s11064-008-9855-x.

Schapira, AHV; (2008) Controlling motor symptoms and fluctuations in adjunct therapy. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 418 - 418). BLACKWELL PUBLISHING

Schapira, AHV; (2008) Rasagiline in neurodegeneration. EXP NEUROL , 212 (2) 255 - 257. 10.1016/j.expneurol.2008.05.002.

Schapira, AHV; (2008) Progress in neuroprotection in Parkinson's disease. EUR J NEUROL , 15 5 - 13.

Schapira, AHV; (2008) The scientific and clinical basis for future therapies in Parkinson's disease - Foreword. EUR J NEUROL , 15 V - V.

Schapira, AHV; (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. MOVEMENT DISORD , 23 S515 - S520. 10.1002/mds.22146.

Schapira, AHV; (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. LANCET NEUROL , 7 (1) 97 - 109.

Schapira, AHV; Borgohain, R; Stocchi, F; Lorenzana, P; Onofrj, M; Lucini, V; Giuliani, R; (2008) Long-term safety and efficacy of safinamide added to dopamine agonists in early Parkinson's disease (PD). In: NEUROLOGY. (pp. A424 - A424). LIPPINCOTT WILLIAMS & WILKINS

Schapira, AHV; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: the impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 132 - 132). BLACKWELL PUBLISHING

Schapira, AHV; Olanow, CW; (2008) Drug Selection and Timing of Initiation of Treatment in Early Parkinson's Disease. ANN NEUROL , 64 (6) S47 - S55. 10.1002/ana.21460.

Schapira, AHV; Stocchi, F; Hunter, B; Giorgi, L; (2008) Adjunctive ropinirole 24-hour prolonged release compared with adjunctive ropinirole immediate release in patients with advanced PD: results from a per-protocol analysis of the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 131 - 132). BLACKWELL PUBLISHING

Schapira, AHV; Stocchi, F; Hunter, B; Giorgi, L; (2008) Comparison of adjunctive ropinirole 24-hour prolonged release and ropinirole immediate release in patients with advanced Parkinson's disease: A per-protocol analysis of the PREPARED study. In: MOVEMENT DISORDERS. (pp. S196 - S197). WILEY-LISS

Stocchi, F; Hunter, B; Giorgi, L; Schapira, AHV; (2008) Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinson's disease (PD): the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 134 - 134). BLACKWELL PUBLISHING

Stocchi, F; Hunter, B; Giorgi, L; Schapira, AHV; (2008) On evaluation of symptom control in patients with advanced PD receiving adjunctive ropinirole 24-hour prolonged release versus ropinirole immediate release: results from the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 134 - 134). BLACKWELL PUBLISHING

Stocchi, F; Huter, B; Giorgi, L; Schapira, AHV; (2008) Comparison of adjunctive ropinirole 24-hour prolonged release and ropinirole immediate release in patients with advanced Parkinson's disease: The PREPARED study. In: MOVEMENT DISORDERS. (pp. S215 - S216). WILEY-LISS

Tan, EK; Schapira, AH; (2008) Hunting for genes in essential tremor. EUR J NEUROL , 15 (9) 889 - 890. 10.1111/j.1468-1331.2008.02226.x.

Tan, EK; Schapira, AH; (2008) Uniting Chinese across Asia: The LRRK2 Gly2385Arg risk variant. EUR J NEUROL , 15 (3) 203 - 204. 10.1111/j.1468-1331.2007.02053.x.

Yamamoto, M; Schapira, AH; (2008) Dopamine agonists in Parkinson's disease. Expert Rev Neurother , 8 (4) 671 - 677. 10.1586/14737175.8.4.671.

2007

Schapira, AHV and Byrne, E and Dimauro, S and Frackowiak, RSJ and Johnson, RT and Mizuno, Y and Samuels, MA and Silberstein, SD and Wszolek, ZK (Eds). (2007) Neurology and clinical neuroscience - a textbook of neurology. Elsevier: Philadelphia.

Anand, R; Onofrj, M; Schapira, AH; Rossetti, SM; (2007) Safinamide potentiates the effects of DA-agonists in early stage Parkinson's disease (PD) patients. In: MOVEMENT DISORDERS. (pp. S244 - S244). WILEY-LISS

Barone, P; Goetz, CG; Houben, J; Juergen, K; Leentjens, AFG; Poewe, W; Rascol, OO; (2007) PRODEST study: depressive symptoms in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S183 - S183). WILEY-LISS

Barone, P; Goetz, CG; Houben, JJ; Koester, J; Leentjens, AF; Poewe, W; Rascol, O; (2007) Prodest - Depressive symptoms in Parkinson's disease: Demographic data. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 61 - 61). BLACKWELL PUBLISHING

Barone, P; Goetz, CG; Houben, JJ; Koster, J; Leentjens, AFG; Powe, W; Rascol, O; (2007) PRODEST - Depressive symptoms in Parkinson's disease: Pattern across scales. PARKINSONISM RELAT D , 13 S51 - S51.

Chaudhuri, KR; Martinez-Martin, P; Brown, RG; Sethi, K; Stocchi, F; Odin, P; Ondo, W; (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. MOVEMENT DISORD , 22 (13) 1901 - 1911. 10.1002/mds.21596.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; Brown, RG; (2007) International validation of the first non-motor questionnaire (NMSQuest) and scale (NMSS) for Parkinson's disease. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 213 - 213). B M J PUBLISHING GROUP

Cooper, JM; Schapira, AHV; (2007) Friedreich's ataxia: Coenzyme Q(10) and vitamin E therapy. MITOCHONDRION , 7 S127 - S135. 10.1016/j.mito.2007.04.001.

Giladi, N; Boroojerdi, B; Korczyn, AD; Burn, DJ; Clarke, CE; Schapira, AH; SP513 Investigators, ; (2007) Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. MOVEMENT DISORD , 22 (16) 2398 - 2404. 10.1002/mds.21741.

Ginsberg, L; Daras, M; Davie, C; Albrecht, J; Schapira, AHV; Weatherall, M; Taanman, JW; (2007) A novel MNGIE mutation. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 238 - 238). BLACKWELL PUBLISHING

Ginsberg, L; Schapiro, AHV; Taanman, JM; (2007) Relapsing neuropathy in an 18-year-old woman. LANCET NEUROL , 6 (2) 192 - 198.

Lynch, JM; Sisodiya, SM; (2007) Genetics of epilepsy. In: Schapira, AHV, (ed.) Neurology and clinical neuroscience. (681 - 689). Mosby/Elsevier: Philadelphia. Green open access
file

Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; MacPhee, G; Brown, RG; (2007) Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. MOVEMENT DISORD , 22 (11) 1623 - 1629. 10.1002/mds.21586.

Pienaar, I; Carr, J; Hattingh, S; Morten, K; Schallert, T; Schapira, AH; Daniels, W; (2007) A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. PARKINSONISM RELAT D , 13 S91 - S91.

Pienaar, I; Carr, J; Hattingh, S; Morten, K; Schallert, T; Schapira, AH; Daniels, W; (2007) A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. PARKINSONISM RELAT D , 13 S133 - S133.

Schapira, AH; (2007) Mitochondria in the etiology of Parkinson's disease. Handb Clin Neurol , 83 479 - 491. 10.1016/S0072-9752(07)83022-3.

Schapira, AHV; (2007) Ropinirole 24-hour extended release for Parkinson's disease. In: AKTUELLE NEUROLOGIE. (pp. S15 - S17). GEORG THIEME VERLAG KG

Schapira, AHV; (2007) Treatment options in the modern management of Parkinson Disease. ARCH NEUROL-CHICAGO , 64 (8) 1083 - 1088.

Schapira, AHV; (2007) Mitochondrial dysfunction in Parkinson's disease. CELL DEATH DIFFER , 14 (7) 1261 - 1266. 10.1038/sj.cdd.4402160.

Schapira, AHV; (2007) Future directions in the treatment of Parkinson's disease. MOVEMENT DISORDERS , 22 S385 - S391. 10.1002/mds.21679.

Schapira, AHV; (2007) Metabolic causes of ataxia. In: Brice, A and Pulst, SM, (eds.) Spinocerebellar degenerations: the ataxias and spastic paraplegias. (255 - 267). Butterworth-Heinemann Elsevier: Philadelphia.

Schapira, AHV; (2007) Mitochondria in Movement Disorders. In: Jankovic, J and Tolosa, E, (eds.) Parkinson's Disease & Movement Disorders. (284 - 297). Lippincott Williams & Wilkins: Philadelphia.

Schapira, AHV; (2007) Mitochondria in the etiology of Parkinson's disease. In: Koller, WC and Melamed, E, (eds.) Parkinson's disease and related disorders, part I. (481 - 491). Elsevier: Edinburgh.

Schapira, AHV; Chau, KY; Cooper, JM; (2007) Cabergoline protects against paraquant and alpha-synuclein mutation toxicity. In: NEUROLOGY. (pp. A110 - A110). LIPPINCOTT WILLIAMS & WILKINS

Sharma, T; Stocchi, F; Schapira, AH; Borgohain, R; LoreDzana, P; Onoftj, M; Rossetti, S; (2007) Satinamide treatment improves cognition in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. XII - XIII). WILEY-LISS

Simonson, W; Hauser, RA; Schapira, AHV; (2007) Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. ANN PHARMACOTHER , 41 (11) 1842 - 1849. 10.1345/aph.1K348.

Turner, C; Cooper, JM; Schapira, AHV; (2007) Clinical correlates of mitochondrial function in Huntington's disease muscle. MOVEMENT DISORD , 22 (12) 1715 - 1721. 10.1002/mds.21540.

Warner, TT; (2007) Dystonia. In: Schapira, AHV, (ed.) Neurology and Clinical Neurosciences. (443 - 454). Mosby Elsevier: Philadelphia.

2006

Cano, SJ; Hobart, JC; Hart, PE; Kolipara, LVP; Schapira, AHV; Cooper, JM; (2006) International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia? In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 133 - 133). B M J PUBLISHING GROUP

Cano, SJ; Riazi, A; Cooper, JM; Schapira, AHV; Hobart, JC; (2006) The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 133 - 133). B M J PUBLISHING GROUP

Chaudhuri, KR; Healy, DG; Schapira, AHV; (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. LANCET NEUROL , 5 (3) 235 - 245.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Sethi, K; Ondo, W; Stocchi, F; Odin, P; (2006) International validation of the first united non motor symptoms scale for Parkinson's disease. Results from the first pilot NMSS study. In: NEUROLOGY. (pp. A124 - A124). LIPPINCOTT WILLIAMS & WILKINS

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; Brown, RG; (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. MOVEMENT DISORD , 21 (7) 916 - 923. 10.1002/mds.20844.

Iravani, MM; Haddon, CO; Cooper, JM; Jenner, P; Schapira, AH; (2006) Pramipexole protects against MPTP toxicity in non-human primates. J NEUROCHEM , 96 (5) 1315 - 1321. 10.1111/j.1471-4159.2005.03625.x.

Lodi, R; Tonon, C; Calabrese, V; Schapira, AHV; (2006) Friedreich's ataxia: From disease mechanisms to therapeutic interventions. ANTIOXID REDOX SIGN , 8 (3-4) 438 - 443.

Naidu, Y; Schapira, AH; Martinez-Martin, P; Sethi, K; Odin, P; Stocchi, F; Ondo, W; (2006) International validation study of the first comprehensive unified Nonmotor Symptoms Scale (NMSS) for Parkinson's disease (PD). In: MOVEMENT DISORDERS. (pp. S613 - S613). WILEY-LISS

Olanow, CW; Schapira, AHV; LeWitt, PA; Kieburtz, K; Sauer, D; Olivieri, G; Pohlmann, H; (2006) TCH346 as a neuroprotective drug in Parkinson"s disease: a double-blind, randomised, controlled trial. LANCET NEUROL , 5 (12) 1013 - 1020. 10.1016/S1474-4422(06)70602-0.

Riazi, A; Cano, SJ; Cooper, JM; Bradley, JL; Schapira, AHV; Hobart, JC; (2006) Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes? MOVEMENT DISORD , 21 (9) 1396 - 1403. 10.1002/mds.20985.

Schapira, A.H.V.; Cleeter, M.W.J.; Muddle, J.R.; Workman, J.M.; Cooper, J.M.; King, R.H.M.; (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Annals of Neurology , 60 (2) pp. 253-255. 10.1002/ana.20934.

Schapira, AH; (2006) Scientific basis for neuroprotection in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S14 - S14). WILEY-LISS

Schapira, AH; (2006) The use of rasagiline in Parkinson's disease. journal of neural transmission , 71 1 - 5.

Schapira, AHV; (2006) Parkinson's disease. In: Schapira, AHV, (ed.) Neurology and clinical neuroscience. (927 - 960). Mosby/Elsevier: Philadelphia.

Schapira, AHV; (2006) Sudden onset of sleep and daytime drowsiness in Parkinson's disease. In: JOURNAL OF THE NEUROLOGICAL SCIENCES. (pp. 319 - 319). ELSEVIER SCIENCE BV

Schapira, AHV; (2006) RLS patients: who are they? EUR J NEUROL , 13 2 - 7.

Schapira, AHV; (2006) Restless Legs Syndrome - Preface. EUR J NEUROL , 13 1 - 1.

Schapira, AHV; (2006) Improving the management of Parkinson's disease: New ropinirole data from EASE-PD in context. EUR J NEUROL , 13 317 - 317.

Schapira, AHV; (2006) Non-motor symptoms. EUR J NEUROL , 13 316 - 317.

Schapira, AHV; (2006) The importance of LRRK2 mutations in Parkinson disease. ARCH NEUROL-CHICAGO , 63 (9) 1225 - 1228.

Schapira, AHV; (2006) Mitochondrial disease. LANCET , 368 (9529) 70 - 82.

Schapira, AHV; (2006) Mitochondria in neurodegeneratives diseases. In: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. (pp. S82 - S83). CAMBRIDGE UNIV PRESS

Schapira, AHV; (2006) Etiology of Parkinson's disease. NEUROLOGY , 66 (10) S10 - S23.

Schapira, AHV; (2006) The use of rasagiline in Parkinson's disease. J NEURAL TRANSM-SUPP (71) 157 - 161.

Schapira, AHV; Bezard, E; Brotchie, J; Calon, F; Collingridge, GL; Ferger, B; Hengerer, B; (2006) Novel pharmacological targets for the treatment of Parkinson's disease. NAT REV DRUG DISCOV , 5 (10) 845 - 854. 10.1038/nrd2087.

Schapira, AHV; Cleeter, MWJ; Muddle, JR; Workman, JM; Cooper, JM; King, RHM; (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. ANN NEUROL , 60 (2) 253 - 255. 10.1002/ana.20934.

Schapira, AHV; Muddle, JR; Workman, JM; Cleeter, MWJ; Cooper, MJ; King, RHM; (2006) Systemic proteasomal inhibition causes loss of nigral TH positive neurons. In: NEUROLOGY. (pp. A146 - A146). LIPPINCOTT WILLIAMS & WILKINS

Schapira, AHV; Obeso, J; (2006) Timing of treatment initiation in Parkinson's disease: A need for reappraisal? ANN NEUROL , 59 (3) 559 - 562.

Schapira, AHV; Obeso, JA; (2006) Treatment should not be initiated too soon in Parkinson's disease - Reply. ANN NEUROL , 59 (3) 564 - 565.

Stacey, M; Hauser, R; Oertel, W; Schapira, AH; Sethi, K; Stocchi, F; Tolosa, E; (2006) End of dose wearing off in Parkinson's disease; A 9-question survey assessment. Clinical Pharmacology , 29 (6) 312 - 321.

Stacy, M; Hauser, R; Oertel, W; Schapira, A; Sethi, K; Stocchi, F; Tolosa, E; (2006) End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol , 29 (6) 312 - 321. 10.1097/01.WNF.0000232277.68501.08.

Tsuboi, Y; Yamada, T; Chaudhuri, RK; Martinez-Martin, P; Schapira, AH; P International, ; (2006) Comparison of profile of non motor symptoms in Japanese patients with PD with Euoprean patients and healthy controls. Extension of the NMSQuest study. In: MOVEMENT DISORDERS. (pp. S648 - S649). WILEY-LISS

2005

Baracca, A; Solaini, G; Sgarbi, G; Lenaz, G; Baruzzi, A; Schapira, AHV; Martinuzzi, A; (2005) Severe impairment of complex I-Driven adenosine triphosphate synthesis in Leber hereditary optic neuropathy cybrids. ARCH NEUROL-CHICAGO , 62 (5) 730 - 736.

Cano, SJ; Hobart, JC; Hart, PE; Korlipara, LVP; Schapira, AH; Cooper, JM; (2005) International Cooperative Ataxia Rating Scale (ICARS): Appropriate for studies of Friedreich's ataxia? MOVEMENT DISORD , 20 (12) 1585 - 1591. 10.1002/mds.20651.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Ondo, W; Sethi, K; PD NMS Scale Dev Grp, ; (2005) An international multicentre study validating the first screening questionnaire (NMS-quest) for comprehensive assessment of non motor symptoms of Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S50 - S50). WILEY-LISS

Danielson, SR; Carelli, V; Tan, GL; Martinuzzi, A; Schapira, AHV; Savontaus, ML; Cortopassi, GA; (2005) Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. BRAIN , 128 1026 - 1037. 10.1093/brain/awh447.

Gu, M; Iravani, MM; Cooper, JM; King, D; Jenner, P; Schapira, AHV; (2005) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms (vol 91, pg 1075, 2004). J NEUROCHEM , 92 (1) 215 - 215. 10.1111/j.1471-4159.2004.02966.x.

Hart, PE; Lodi, R; Rajagopalan, B; Bradley, JL; Crilley, JG; Turner, C; Blamire, AM; (2005) Antioxidant treatment of patients with Friedreich ataxia - Four-year follow-up. ARCH NEUROL-CHICAGO , 62 (4) 621 - 626.

Lo, S; Tolner, B; Taanman, JW; Cooper, JM; Gu, M; Hartley, JA; Schapira, AHV; (2005) Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. INT J ONCOL , 27 (2) 337 - 344.

Schapira, A; Bate, G; Kirkpatrick, P; (2005) Rasagiline. Nat Rev Drug Discov , 4 (8) 625 - 626. 10.1038/nrd1803.

Schapira, AH; (2005) Rasagiline, a novel second generation MAO-B inhibitor - pharmacological profile. EUR J NEUROL , 12 329 - 329.

Schapira, AH; (2005) Mitochondrial DNA and disease: what happens when things go wrong? The Biochemist , 27 (3) 24 - 27.

Schapira, AHV; (2005) Present and future drug treatment for Parkinson's disease. J NEUROL NEUROSUR PS , 76 (11) 1472 - 1478. 10.1136/jnnp.2004.035980. Gold open access

Schapira, AHV; Olanow, CW; (2005) Principles of treatment in Parkinson's disease. Butterworth-Heinemann

Strand, AD; Aragaki, AK; Shaw, D; Bird, T; Holton, J; Turner, C; Tapscott, SJ; (2005) Gene expression in Huntington's disease skeletal muscle: a potential biomarker. HUM MOL GENET , 14 (13) 1863 - 1876. 10.1093/hmg/ddi192.

Taanman, JW; Schapira, AHV; (2005) Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. NEUROSCI LETT , 376 (1) 56 - 59. 10.1016/j.neulet.2004.11.023.

Tabrizi, SJ; Blamire, AM; Manners, DN; Rajagopalan, B; Styles, P; Schapira, AHV; Warner, TT; (2005) High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. NEUROLOGY , 64 (9) 1655 - 1656.

2004

Beretta, S; Mattavelli, L; Sala, G; Tremolizzo, L; Schapira, AHV; Martinuzzi, A; Carelli, V; (2004) Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. BRAIN , 127 2183 - 2192. 10.1093/brain/awh258.

Bradley, J.L.; Homayoun, S.; Hart, P.E.; Schapira, A.H.V.; Cooper, J.M.; (2004) Role of oxidative damage in Friedreich's Ataxia. Neurochemical Research , 29 (3) pp. 561-567. 10.1023/B:NERE.0000014826.00881.c3.

Bradley, JL; Homayoun, S; Hart, PE; Schapira, AHV; Cooper, JM; (2004) Role of oxidative damage in Friedreich's ataxia. NEUROCHEM RES , 29 (3) 561 - 567.

Chaudhuri, K; Schapira, AH; Martinez-Martin, P; Brown, K; (2004) On behalf of the International Parkinson's Disese Non-Motor Symptom Scale Development Group. Can we improve the holistic assessment of Parkinson's disease? The development of a non-motor symptom questionnaire adn scale for PD:. Advances in Clinical Neuroscience and Rehabilitation , 4 20 - 21.

Chaudhuri, KR; Forbes, A; Grosset, D; Lees, A; Shneerson, J; Schapira, A; Stillman, P; (2004) Diagnosing restless legs syndrome (RLS) in primary care. CURR MED RES OPIN , 20 (11) 1785 - 1795. 10.1185/030079904X5472.

Chaudhuri, KR; Schapira, AHV; Martinez-Martin, P; Sethi, K; MacPhee, G; Brown, R; Odin, P; (2004) Development and pilot study of the first nonmotor symptom screening questionnaire and scale for Parkinson's disease using an international multidisciplinary approach. In: MOVEMENT DISORDERS. (pp. 1120 - 1120). WILEY-LISS

Davie, CA; Schapira, AH; (2004) Use of COMT inhibitors in the treatment of Parkinson's disease. Clinical Geriatrics , 12 (6) 19 - 24.

Francis, J; Cooke, F; Bradley, JL; Blamire, AM; Schapira, AHV; Neubauer, S; Cooper, JM; (2004) Myocardial. hypertrophy in Friedreich's ataxia (FA) is a function of duration of the disease and the length of the GAA trinucleotide repeat; A cross sectional MRI study. In: HEART. (pp. A58 - A58). B M J PUBLISHING GROUP

Gu, M; Irvani, M; Cooper, JM; King, D; Jenner, P; Schapira, AHV; (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J NEUROCHEM , 91 (5) 1075 - 1081. 10.1111/j.1471-4159.2004.02804.x.

Korlipara, LVP; Cooper, JM; Schapira, AHV; (2004) Oxidative stress in a neuronal model of alpha synuclein overexpression. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 1226 - 1226). B M J PUBLISHING GROUP

Korlipara, LVP; Cooper, JM; Schapira, AHV; (2004) Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. NEUROPHARMACOLOGY , 46 (4) 562 - 569. 10.1016/j.neuropharm.2003.10.015.

MacMahon, D; Koller, W; Martinex-Martin, P; Chaudhuri, K; Schapira, A; Sethi, K; Brown, R; (2004) Can we improve the holistic assessment of Parkinson's disease? The development of a non-motor symptom questionnaire and scale for Parkinson's disease. Advances in Clinical Opinions , 20 1785 - 1795.

McCabe, DJH; Turner, NC; Chao, D; Leff, A; Gregson, NA; Womersley, HJ; Mak, I; (2004) Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. NEUROLOGY , 62 (8) 1402 - 1404.

Olanow, CW; Schapira, AHV; (2004) Measuring the effects of therapy in Parkinson disease - Reply. JAMA-J AM MED ASSOC , 291 (20) 2431 - 2431.

Orth, M; Tabrizi, SJ; Tomlinson, C; Messmer, K; Korlipara, LVP; Scapira, AHV; Cooper, JM; (2004) G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. NEUROCHEM INT , 45 (5) 669 - 676. 10.1016/j.neuint.2004.03.029.

Page, RA; Davie, CA; MacManus, D; Miszkiel, KA; Walshe, JM; Miller, DH; Lees, AJ; (2004) Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. NEUROLOGY , 63 (4) 638 - 643.

Rafique, R; Schapira, AHV; Cooper, JM; (2004) Mitochondrial respiratory chain dysfunction in ageing; Influence of vitamin E deficiency. FREE RADICAL RES , 38 (2) 157 - 165. 10.1080/10715760310001643311.

Samii, A; Nutt, JG; Ransom, BR; (2004) Parkinson's disease. (Vol.363).

Schapira, A; (2004) Understanding Parkinson's Disease. Pool: Family Doctor Association. British Medical Association: London.

Schapira, A; Lodi, R; (2004) Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. Methods Mol Biol , 277 293 - 307. 10.1385/1-59259-804-8:293.

Schapira, AH; (2004) Excessive daytime sleepiness in Parkinson's disease. NEUROLOGY , 63 (8) S24 - S27.

Schapira, AH; (2004) Disease modification in Parkinson's disease. Lancet Neurol , 3 (6) 362 - 368. 10.1016/S1474-4422(04)00769-0.

Schapira, AH; (2004) Disease of muscle and the neuromuscular junction. Clinical Neurology 130 - 153.

Schapira, AHV; (2004) Disease modification in Parkinson's disease. (vol 3, pg 362, 2004). LANCET NEUROL , 3 (7) 443 - 443.

Schapira, AHV; (2004) Restless legs syndrome - An update on treatment options. DRUGS , 64 (2) 149 - 158.

Schapira, AHV; Chaudhuri, KR; Gershanik, O; Stocchi, F; (2004) Understanding the importance of the nocturnal symptoms of Parkinson's disease: Diagnosis, treatment, and quality of life. EUR J NEUROL , 11 357 - 357.

Schapira, AHV; Olanow, CW; (2004) Neuroprotection in Parkinson disease - Mysteries, myths, and misconceptions. JAMA-J AM MED ASSOC , 291 (3) 358 - 364.

Tabrizi, SJ; Blamire, AM; Rajagopalan, B; Manners, D; Schapira, AH; Warner, TT; (2004) High dose creatine therapy for Huntington's disease: Clinical and 31 phosphorous magnetic resonance spectroscopy ((31P) MRS) findings in a 2-year study. In: MOVEMENT DISORDERS. (pp. S51 - S51). WILEY-LISS

Wilkinson, PA; Crosby, AH; Turner, C; Bradley, LJ; Ginsberg, L; Wood, NW; Schapira, AH; (2004) A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. BRAIN , 127 973 - 980. 10.1093/brain/awh125.

2003

Cooper, JM; Schapira, AHV; (2003) Friedreich's Ataxia: Disease mechanisms, antioxidant and coenzyme Q(10) therapy. BIOFACTORS , 18 (1-4) 163 - 171.

Cortopassi, G; Tong, W; Wong, A; Carelli, V; Martinuzzi, A; Schapira, AHV; Danielson, SR; (2003) Mitochondrial fusion and Leber's hereditary optic neuropathy mtDNA point mutations cause altered nuclear gene expression. In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. (pp. U395 - U395). ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Ghelli, A; Zanna, C; Porcelli, AM; Schapira, AH; Martinuzzi, A; Carelli, V; Rugolo, M; (2003) Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. Journal of Biological Chemistry , 278 (6) 4146 - 4150. Gold open access

Ghelli, A; Zanna, C; Porcelli, AM; Schapira, AHV; Martinuzzi, A; Carelli, V; Rugolo, M; (2003) Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. J BIOL CHEM , 278 (6) 4145 - 4150. 10.1074/jbc.M210285200. Gold open access

Lodi, R; Rajagopalan, B; Schapira, AHV; Cooper, JM; (2003) Cardiac bioenergetics in Friedreich's ataxia. ANN NEUROL , 54 (4) 552 - 552. 10.1002/ana.10744.

Lodi, R; Rajagopalan, B; Schapira, AHV; Hart, P; Crilley, JG; Bradley, JL; Blamire, AM; (2003) Coenzyme Q10 and vitamin E treatment in patients with Friedreich ataxia improves cardiac bioenergetics and mechnical function. A 4 year clinical and 31 P-magnetic resonance spectroscopy study. In: HEART. (pp. A43 - A43). B M J PUBLISHING GROUP

Miller, RF; Shahmanesh, M; Hanna, MG; Unwin, RJ; Schapira, AHV; Weller, IVD; (2003) Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors. ANTIVIR THER , 8 (3) 253 - 257.

Olanow, CW; Schapira, AHV; Agid, Y; (2003) Neuroprotection for Parkinson's disease: Prospects and promises. ANN NEUROL , 53 S1 - S2.

Orth, M; Cooper, JM; Bates, GP; Schapira, AHV; (2003) Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J NEUROCHEM , 87 (1) 1 - 6. 10.1046/j.1471-4159.2003.02009.x.

Orth, M; Tabrizi, SJ; Schapira, AHV; Cooper, JM; (2003) alpha-Synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. NEUROSCI LETT , 351 (1) 29 - 32. 10.1016/S0304-3940(03)00941-8.

Schapira, AHV; (2003) Disease-modifying strategies and challenges in PD - Interactive breakout sessions. NEUROLOGY , 61 (6) S56 - S63.

Schapira, AHV; (2003) Neuroprotection in PD - A role for dopamine agonists? NEUROLOGY , 61 (6) S34 - S42.

Schapira, AHV; (2003) Progress in Parkinson's disease. NEUROLOGY , 61 (6) S1 - S3.

Schapira, AHV; (2003) Diseases of muscle and the neuromuscular junction. In: Fowler, TJ and Scadding, JW, (eds.) Clinical neurology. (130 - 153). Arnold: London.

Schapira, AHV; Gu, M; Cooper, JM; (2003) Dopamine agonist mediated neuroprotection: Mechanisms of action. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 1179 - 1179). BRITISH MED JOURNAL PUBL GROUP

Schapira, AHV; Olanow, CW; (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. ANN NEUROL , 53 S149 - S157. 10.1002/ana.10514.

Tabrizi, SJ; Blamire, AM; Manners, DN; Rajagopalan, B; Styles, P; Schapira, AHV; Warner, TT; (2003) Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study. NEUROLOGY , 61 (1) 141 - 142.

Turner, C; Schapira, AHV; (2003) Energy metabolism and Huntington's disease. In: Bates, G and Harper, P and Jones, L, (eds.) Huntington's disease. Oxford University Press

Warner, TT; Schapira, AHV; (2003) Genetic and environmental factors in the cause of Parkinson's disease. ANN NEUROL , 53 S16 - S23. 10.1002/ana.10487.

Wilkinson, PA; Crosby, AH; Turner, C; Patel, H; Wood, NW; Schapira, AH; Warner, TT; (2003) A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. NEUROLOGY , 61 (2) 235 - 238.

2002

Bentley, PI; Kimber, T; Schapira, AHV; (2002) Painful third nerve palsy in MS. NEUROLOGY , 58 (10) 1532 - 1532.

Bradley, JL; Hart, PE; Al Khayatt, M; Schapira, AH; Cooper, J; (2002) Validation and use of assessment protocols to determine clinical progression in Friedreich's ataxia. In: MOVEMENT DISORDERS. (pp. S315 - S315). WILEY-LISS

Bradley, JL; Schapira, AH; Cooper, JM; (2002) Therapies for Friedreich's ataxia. EuroAtaxia Newsletter , 22 8 - 11.

Cock, HR; Schapira, AHV; (2002) A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM-INT J MED , 95 (4) 225 - 231.

Cock, HR; Tong, X; Hargreaves, IP; Heales, SJR; Clark, JB; Patsalos, PN; Thom, M; (2002) Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. EPILEPSY RES , 48 (3) 157 - 168.

Danielson, SR; Wong, A; Carelli, V; Martinuzzi, A; Schapira, AHV; Cortopassi, GA; (2002) Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-induced apoptosis. J BIOL CHEM , 277 (8) 5810 - 5815. 10.1074/jbc.M110119200. Gold open access

Davie, CA; Schapira, AHV; (2002) Wilson disease. In: UNSPECIFIED (175 - 190). ACADEMIC PRESS INC

DiMauro, S; Schapira, AHV; (2002) Mitochondrial encephalomyopathies. In: Asbury, AK and McKhann, GM and McDonald, WI and Goadsby, PJ and McArthur, JC, (eds.) Diseases of the nervous system: clinical neuroscience and therapeutic principles. (1922 - 1936). Cambridge University Press: Cambridge.

Hart, PE; De Vivo, DC; Schapira, AH; (2002) Clinical features of the mitochondrial encephalomyopathies. In: Schapira, AH and DiMauro, S, (eds.) Mitochondrial Disorders in Neurology. (35 - 68). Butterworth Heinemann: Massachusetts.

Korlipara, LP; Messmer, K; Cooper, JM; Schapira, AHV; (2002) Overexpression of wild-type and mutant alpha-synuclein in a neuroblastoma cell line. In: MOVEMENT DISORDERS. (pp. S61 - S61). WILEY-LISS

Korlipara, LV; Schapira, AH; (2002) Parkinson's disease. In: UNSPECIFIED (283 - 314).

Korlipara, LVP; Burn, DJ; Schapira, AHV; (2002) Juvenile-onset parkinsonism in a patient with Chediak-Higashi syndrome: A case report. In: MOVEMENT DISORDERS. (pp. S254 - S254). WILEY-LISS

Korlipara, LVP; Schapira, AH; (2002) Possible Mechanisms Underlying the Protective Action of Immunosuppressants Against Parkinson's Disease. The Mitochondrial Permeability Transition Pore Hypothesis. In: Borlongan, CV and Isacson, O and Sanberg, PR, (eds.) Immunosuppressant Analogs in Neuroprotection. (105 - 137). Humana Press: Totowa, New Jersey.

Korlipara, LVP; Schapira, AHV; (2002) Neuroprotection in Parkinson's disease. MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE , 51 373 - 378.

Korlipara, LVP; Schapira, AHV; (2002) Parkinson's disease. INT REV NEUROBIOL , 53 283 - 314.

Lodi, R; Rajagopalan, B; Bradley, JL; Taylor, DJ; Crilley, JG; Hart, PE; Blamire, AM; (2002) Mitochondrial dysfunction in Friedreich's ataxia: From pathogenesis to treatment perspectives. FREE RADICAL RESEARCH , 36 (4) 461 - 466. 10.1080/10715760290021324.

Lodi, R; Rajagopalan, B; Crilley, JG; Cooper, JM; Styles, P; Schapira, AHV; (2002) Cardiac hypertrophy in Friedreich's ataxia - Reply to letter to the editor. CARDIOVASC RES , 54 (3) 695 - 696.

Orrell, R; Schapira, AH; (2002) Mitochondria and amyotrophic lateral sclerosis. International Review of Neurobiology , 53 411 - 424.

Orrell, RW; Schapira, AHV; (2002) Mitochondria and amyotrophic lateral sclerosis. In: UNSPECIFIED (411 - 426). ACADEMIC PRESS INC

Orth, M; Schapira, AHV; (2002) Mitochondrial involvement in Parkinson's disease. NEUROCHEM INT , 40 (6) 533 - 541.

Schapira, AH; (2002) Mitochondrial Function and Dysfunction. International Review of Neurobiology: Vol.53. Academic Press

Schapira, AH; DiMauro, S; (2002) Mitochondrial Disorders in Neurology. (2nd ed.). Butterworth Heinemann: Massachusetts.

Schapira, AHV; (2002) Dopamine agonists and neuroprotection in Parkinson's diseae. EUR J NEUROL , 9 7 - 14.

Schapira, AHV; (2002) Primary and secondary defects of the mitochondrial respiratory chain. JOURNAL OF INHERITED METABOLIC DISEASE , 25 (3) 207 - 214.

Schapira, AHV; (2002) Neuroprotection and dopamine agonists. NEUROLOGY , 58 (4) S9 - S18.

Schapira, AHV; (2002) The "new" mitochondrial disorders. J NEUROL NEUROSUR PS , 72 (2) 144 - 149.

Schapira, AHV; Gu, M; King, DF; Cooper, JM; Jenner, P; (2002) Pramipexole protects against rotenone toxicity: Mechanisms and implications. NEUROLOGY , 58 (7) A495 - A495.

Spacey, SD; Valente, EM; Wali, GM; Warner, TT; Jarman, PR; Schapira, AHV; Dixon, PH; (2002) Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene. MOVEMENT DISORD , 17 (4) 717 - 725. 10.1002/mds.10126.

Tabrizi, SJ; Rajagopalan, B; Styles, P; Manners, D; Schapira, AH; Warner, TT; (2002) Creatine therapy for Huntington's disease (HD): Clinical and-(31)phosphorous magnetic resonance spectroscopy (P-31 MRS) findings in a one year pilot. In: MOVEMENT DISORDERS. (pp. S319 - S319). WILEY-LISS

Tabrizi, SJ; Schapira, AHV; (2002) Mitochondrial abnormalities in neurodegenerative disorders. In: Schapira, AHV and DiMauro, S, (eds.) Mitochondrial disorders in neurology 2. (143 - 174). Butterworth-Heinemann: Oxford.

Turner, C; Jones, L; Cooper, JM; Schapira, AHV; (2002) The characterization of Huntington's disease (HD) skeletal muscle: Mitochondrial respiratory chain, ultrastructural and light microscopic study. In: MOVEMENT DISORDERS. (pp. S325 - S325). WILEY-LISS

Turner, C; Jones, L; Elliston, L; Cooper, JM; Schapira, AHV; (2002) In vitro cell models of Huntington's disease using N-terminal and full-length huntingtin: The relationship between excitotoxicity, mitochondrial dysfunction, and free radicals. In: MOVEMENT DISORDERS. (pp. S320 - S321). WILEY-LISS

Turner, C; Schapira, AH; (2002) Energy metabolism and Huntington's Disease. In: Bates, GP and Harper, P and Jones, L, (eds.) Huntington's Disease. (309 - 323). Oxford University Press: Oxford.

2001

Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Grosset, DG; MacMahon, DG; Playfer, J; (2001) Updated guidelines for the management of Parkinson's disease. HOSP MED , 62 (8) 456 - 470.

Cleeter, MW; Cooper, JM; Schapira, AH; (2001) Nitric Oxide enhances MPP+ inhibition of complex I. FEBS Letters , 24 (502(1-2)) 50 - 52. 10.1016/S0014-5793(01)02763-6.

Cleeter, MWJ; Cooper, JM; Schapira, AHV; (2001) Nitric oxide enhances MPP+ inhibition of complex I. FEBS LETT , 504 (1-2) 50 - 52.

Cock, HR; Schapira, AHV; (2001) Mitochondrial myopathies. In: Rose, FC, (ed.) Twentieth Century Neurology: The British Contribution. (255 - 281). Imperial College Press: London.

King, DF; Cooper, JM; Schapira, AHV; (2001) Pramipexole protects against MPP+ toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. NEUROLOGY , 56 (8) A377 - A378.

Kingsbury, AE; Cooper, M; Schapira, AHV; Foster, OJF; (2001) Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study. ANN NEUROL , 50 (2) 142 - 149.

Lodi, R; Hart, PE; Rajagopalan, B; Taylor, DJ; Crilley, JG; Bradley, JL; Blamire, AM; (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. ANN NEUROL , 49 (5) 590 - 596.

Lodi, R; Rajagopalan, B; Blamire, AM; Cooper, JM; Davies, CH; Bradley, JL; Styles, P; (2001) Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo P-31 magnetic resonance spectroscopy study. CARDIOVASC RES , 52 (1) 111 - 119.

Lodi, R; Taylor, DJ; Schapira, AHV; (2001) Mitochondrial dysfunction in Friedreich's ataxia. BIOL SIGNAL RECEPT , 10 (3-4) 263 - 270.

Lodi, R.; Hart, P.E.; Rajagopalan, B.; Taylor, D.J.; Crilley, J.G.; Bradley, J.L.; Blamire, A.M.; (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Annals of Neurology , 49 (5) pp. 590-596. 10.1002/ana.1001.

Lodi, R.; Rajagopalan, B.; Blamire, A.M.; Cooper, J.M.; Davies, C.H.; Bradley, J.L.; Styles, P.; (2001) Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovascular Research , 52 (1) pp. 111-119. 10.1016/S0008-6363(01)00357-1.

Orrell, R; Schapira, AHV; (2001) Asymmetric muscle weakness. In: Schapira, AHV and Rowland, LP, (eds.) Clinical cases in neurology. (239 - 245). Butterworth-Heinemann: Oxford.

Orrell, R; Schapira, AHV; (2001) Muscle weakness and dysphagia. In: Schapira, AHV and Rowland, LP, (eds.) Clinical cases in neurology. (99 - 106). Butterworth-Heinemann: Oxford.

Orth, M; Schapira, AHV; (2001) Prion codon 129 homozygosity and sporadic inclusion body myositis - Reply. NEUROLOGY , 57 (2) 368 - 368.

Orth, M; Schapira, AHV; (2001) Mitochondria and degenerative disorders. AM J MED GENET , 106 (1) 27 - 36.

Page, RA; Davie, CA; MacManus, D; Dooley, J; Walshe, J; Miller, DH; Lees, AJ; (2001) Magnetic resonance spectroscopy of patients with Wilson's disease. J NEUROL NEUROSUR PS , 70 (2) 274 - 275.

Rafique, R; Schapira, AHV; Cooper, JM; (2001) Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. BIOCHEM J , 357 887 - 892.

Rafique, R.; Schapira, A.H.V.; Cooper, J.M.; (2001) Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal , 357 (3) pp. 887-892. 10.1042/0264-6021:3570887.

Schapira, A; Ed, ; (2001) Clinical cases in neurology. Butterworth-Heinemann: Oxford.

Schapira, AHV; (2001) Causes of neuronal death in Parkinson's disease. ADV NEUROL , 86 155 - 162.

Schapira, AHV; Orrell, R; (2001) Young onset stroke. In: Schapira, AHV and Rowland, LP, (eds.) Clinical cases in neurology. (177 - 182). Butterworth-Heinemann: Oxford.

Sharma, P; Wang, T; Brown, MJ; Schapira, AHV; (2001) Fits and strokes. LANCET , 358 (9276) 120 - 120.

Shults, CW; Schapira, AHV; (2001) A cue to queue for CoQ? NEUROLOGY , 57 (3) 375 - 376.

Silva, MT; Schapira, AHV; (2001) Parkinson's disease. In: Mattson, MP, (ed.) Pathogenesis of neurodegenerative disorders. (53 - 79). Humana Press: Totowa,N.J..

Turner, C;